Search

everythingexperts & clinicslearnresearchcommunity

for

Search:↓

Discussion on hair loss treatments, focusing on pp405, with skepticism about its effectiveness and concerns about its association with the cosmetic industry. Users also mention treatments like Minoxidil and Finasteride.

GT20029 showed promising results for hair growth in a Phase II trial, with the 1.0% twice-weekly regimen being the most effective. Some users expressed skepticism and humor about the product's effects and market availability.

GT20029 showed significant hair growth and safety in phase II trials, with no adverse sexual events. Users are hopeful but concerned about future costs and systemic effects.

Genetics mainly cause hair loss, but diet, stress, smoking, and alcohol can worsen it. Treatments include finasteride, minoxidil, and lifestyle changes like a healthy diet and avoiding caffeine.

People are discussing the anticipated release of PP405 phase 2a results, expected by the end of March, with some skepticism about its effectiveness. There is cautious optimism due to past experiences with similar treatments like Breezula, despite concerns about the lack of presentation at the AAD 2026 conference.

PP405 is a safer alternative to JXL069 for hair loss treatment because it penetrates the skin effectively and degrades in the blood, avoiding systemic toxicity. JXL069, when forced into the body, can cause dangerous side effects like lactic acidosis due to its inability to degrade safely.

The conversation discusses anticipation for CB-03-01, a potential new hair loss treatment that may be more effective and have a cleaner safety profile than finasteride. Users are hopeful but cautious, discussing current treatments like minoxidil, nizoral, and dermarolling, and the possibility of combining them with CB-03-01 for better results.

Spironolactone, finasteride, and dutasteride are discussed for hair maintenance, with concerns about testosterone and side effects like gynecomastia. Spironolactone is noted for use in both bodybuilding and hormone therapy, with low doses considered for minimizing side effects.

The conversation discusses whether not masturbating (semen retention) affects hair loss, with opinions varying but generally dismissing the idea. Some participants mention using hair loss treatments like Minoxidil, Finasteride, and RU58841, but the effectiveness and relation to prolactin levels in the scalp are debated.

A 22-year-old male experiencing hair thinning is considering starting finasteride but is concerned about potential side effects and hereditary factors. While waiting to access finasteride, he plans to use pumpkin seed oil, saw palmetto, biotin, and vitamins, and is advised to check blood levels before starting treatment.

Setipiprant and bimatoprost are being discussed as potential future treatments for hair loss. Some individuals have started testing setipiprant before FDA approval, but no progress updates are available yet.

The conversation discusses using PGE2 as a hair growth stimulant, comparing it to minoxidil, and considering the addition of Setipiprant. Concerns about side effects like skin damage and cost are also mentioned.

A 26 year old female diagnosed with androgenetic alopecia who is interested in treatments such as spironolactone, finasteride and Minoxidil to help her hair loss but is worried about side effects like muscle gain, sex drive and effectiveness.

The conversation discusses the fluctuation of testosterone levels in men under 40 and the difference between serum DHT and scalp DHT. It also mentions that DHT levels are higher on Dutasteride than on Finasteride, which is unusual.

Topical spiro's effectiveness on androgens is discussed. User tried oral DUT, oral Min, keto/nizoral, and RU but experienced worsening hair loss and chest pains. Suggestion given to increase dutasteride and oral minoxidil dosage before considering spironolactone.

The conversation discusses starting low-dose oral finasteride for hair loss, considering hormone levels and potential side effects like gynecomastia. Suggestions include using DIM for estradiol, vitamin B6 for prolactin, and lifestyle changes to optimize hormone profiles before starting treatment.

Norwood 7 hair loss is often excluded from trials to ensure treatments appear more effective and to reduce costs. Some believe treatments effective for Norwood 5 could work on Norwood 7, but companies prioritize market readiness.

The conversation discusses affordable options for topical Finasteride, including products like Morr F, 82F, and Essengen 6 Plus, with concerns about availability and cost. The user is seeking effective and convenient solutions, considering options like compounding pharmacies and homemade solutions.

The conversation discusses the use of finasteride for hair loss, comparing every day (ED) versus every other day (EOD) dosing. It suggests that both dosing schedules can be effective, but individual tolerance may vary.

An 18-year-old is seeking advice on their hair loss pattern and potential treatments. They are considering using Minoxidil, finasteride, and RU58841.

The conversation humorously discusses the unfairness of hair loss, highlighting various treatments like finasteride, minoxidil, red light therapy, and experimental drugs, while contrasting with people who have great hair despite unhealthy lifestyles. The original poster mentions experiencing side effects from switching to oral finasteride.

The conversation discusses the potential effectiveness and future results of the hair loss treatment pp405, with questions about its impact on different hair loss stages and areas. There is anticipation for phase 3 trial results to provide more data, and hope that pp405 could enhance hair transplant outcomes.

The user is considering starting finasteride for hair loss but is concerned about potential side effects due to their estradiol levels being near the upper limit. They have consulted a doctor who confirmed their levels are okay to start the treatment.

Hair loss treatments discussed include Minoxidil, Finasteride, and RU58841. Topical and oral spironolactone show potential in improving hair growth when combined with topical Minoxidil.

The conversation discusses experiences with topical dutasteride for hair loss, comparing formulations from FUEClinic, MinoxidilMax, and Strut. Users share their results and side effects, with some preferring topical over oral treatments to minimize systemic absorption.

The conversation is about the potential availability of GT20029 on the black market and whether users would try it. Participants advise waiting for phase 3 trial results to ensure safety and efficacy.

Clascoterone is being discussed for hair loss, but its current acne formulation may not be suitable for scalp use due to potential skin irritation and lower dosage compared to Breezula. Users mention other treatments like finasteride, minoxidil, and pyrilutamide, with some expressing skepticism about clascoterone's effectiveness for hair loss.

New product Tomorrowlabs HSF targets hair loss through HIF pathway indirectly by removing scalp iron. Minoxidil and Stemoxydine also relate to HIF pathway.

PP405 is expected to be on the market between 2027 and 2030, with phase 3 trials starting in 2026. There is skepticism about its fast-tracking due to its cosmetic nature, and it may appear on the gray market sooner.

The conversation humorously discusses hair loss treatments, including Minoxidil, finasteride, RU58841, and topical 17 alpha estradiol, with some users joking about transitioning to female to avoid baldness. The overall tone is satirical, emphasizing self-acceptance and the lengths people might consider for hair restoration.